Clint Cary

6PUBLICATIONS
39CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 24, 2025
Longitudinal Evaluation of Circulating Tumor DNA as a Prognostic Biomarker to Detect Molecular Residual Disease in Germ Cell Tumors.

Rebecca Hassoun, Reuben Ben-David, John P Sfakianos

|Sep 03, 2024
Contemporary short-term peri-operative outcomes of open primary retroperitoneal lymph node dissection.

Jacob D McFadden, Timothy A Masterson, Clint Cary

|Sep 01, 2023
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.

Luca Antonelli, Davide Ardizzone, Isamu Tachibana

|Mar 13, 2023
Surgery in Early Metastatic Seminoma: A Phase II Trial of Retroperitoneal Lymph Node Dissection for Testicular Seminoma With Limited Retroperitoneal Lymphadenopathy.

Siamak Daneshmand, Clint Cary, Timothy Masterson

|Feb 02, 2023
Primary Retroperitoneal Lymph Node Dissection for Stage II Seminoma: Is Surgery the New Path Forward?

Isamu Tachibana, Andre Alabd, Yan Tong

|Jun 08, 2022
Primary Retroperitoneal Lymph Node Dissection for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary?

Isamu Tachibana, Sean Q Kern, Antoin Douglawi

Pageof 1